Overview

Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects

Status:
Completed
Trial end date:
2017-12-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics and bioequivalence of Ritonavir tablet 100 mg versus NORVIR 100 mg tablet in healthy Chinese adult participants under fasting or fed condition.
Phase:
Phase 1
Details
Lead Sponsor:
First Affiliated Hospital of Zhejiang University
Collaborators:
Ascletis Pharmaceutical Co., Ltd.
Ascletis Pharmaceuticals Co., Ltd.
Treatments:
Ritonavir